CNCR Loncar Cancer Immunotherapy ETF
Loncar Cancer Immunotherapy TR USD

NAV as of 13-May-2022

14.2958

4 Week: 13.09 - 17.21

52 Week: 13.09 - 32.50

Latest Closing Price

14.33

Premium / Discount

-0.06

Expense Ratio

0.79%

Investment Objective

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.

Main Fund Characteristics

Fund Manager:
Loncar Investments
Asset Under Management:
19,674,545
Launch Date:
12/10/2015
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
31
Trading Currency:
USD
Style:
Mid Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-39.732.90-13.68
1 Day0.100.000.00
1 Week4.3913.000.34
1 Month-18.5517.28-1.07
3 Months-25.6825.01-1.03
6 Months-49.9531.13-1.60
1 Year-51.6735.78-1.44
2 Years-44.9648.17-0.93
3 Years-30.1361.00-0.49
5 Years-37.1972.75-0.51
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00000.0000-25.350613.0974-20.268424.069936.2193-19.4051
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.000098.000090.0000100.000055.000020.000096.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
28/12/202130/12/20211.8533
27/12/201701/01/20180.3502

Portfolio Data

Total Number of Holdings: 31

Number of Bond Holdings: 0

Number of Equity Holdings: 30

Total Market Value: 19,674,545

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Trillium Therapeutics Inc5.9006165,62602,621,860

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant12.76
Large24.34
Medium10.16
Small20.35
Micro32.29

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

11.9372

Price/Book*

2.5308

Price/Sales*

4.4737

Price/Cash Flow*

8.5331

Dividend Yield*

1.0248

Growth Measures

Long-Term Earnings

10.4426

Historical Earnings

62.9168

Sales Growth

11.9002

Cash-Flow Growth

23.5269

Book-Value Growth

10.6801

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.